Design, Synthesis and Evaluation of Novel Oxazaborine Inhibitors of the NLRP3 Inflammasome

Alex Baldwin, Victor Tapia Olivares, Tessa Swanton, Claire White, James Beswick, David Brough, Sally Freeman

Research output: Contribution to journalArticlepeer-review


The NLRP3 inflammasome is an important regulator of the sterile inflammatory response and its activation by host-derived sterile molecules leads to the intracellular activation of caspase-1, processing of the pro-inflammatory cytokines interleukin-1β (IL 1β)/IL-18, and pyroptotic cell death. Inappropriate activation of NLRP3 drives a chronic inflammatory response and is implicated in several non-communicable diseases, including gout, atherosclerosis, type II diabetes and Alzheimer's disease. In this study, we report the design, synthesis and biological evaluation of novel boron compounds (NBCs) as NLRP3 inflammasome inhibitors. Structure-activity relationships (SAR) show that 4-F groups on the phenyl rings retain NLRP3 inhibitory activity, whereas more steric and lipophilic substituents diminish activity. Loss of inhibitory activity is also observed when the CCl3 group on the oxazaborine ring is replaced by a CF3 group. These findings provide additional understanding of the NBC series and will aid in the development of these NLRP3 inhibitors as tool compounds or therapeutic candidates for sterile inflammatory diseases.
Original languageEnglish
Early online date13 Jan 2018
Publication statusPublished - 2018

Research Beacons, Institutes and Platforms

  • Manchester Institute for Collaborative Research on Ageing


Dive into the research topics of 'Design, Synthesis and Evaluation of Novel Oxazaborine Inhibitors of the NLRP3 Inflammasome'. Together they form a unique fingerprint.

Cite this